Novartis Ag

Nektar Therapeutics

Novartis Pharma Ag

Danforth Miller

Daniel Huang

David Lechuga-Ballesteros

Jeffry G Weers

Thomas E Tarara

Jean-Michel Rene Rondeau

Gino Van Heeke

Hans-Peter Knopf

Reinhard Vehring

Nagaraja P Rao

Nicole Haubst

Matthew John Edwards

Kapil Gupta

Keith Washco

Alan Kugler

Theresa D Sweeney

Trixie Tan

Richard Malcolmson

Barbara Andlauer

Rene Hemmig

Sarvajna Kumar Dwivedi

Michael A Eldon

Sarma Duddu

Srinivas Palakodaty

Christopher Frantz

Gino Anselmus Van Heeke

Embodiments of the invention relate to particulate agents and compositions comprising particulate agents for inhalation, and methods for preparing such particulate agents and compositions for inhalation, as well as therapeutic methods. Embodiments of the method comprise preparing an emulsion by combining an oil phase dispersion of hydrophobic seed particles and an aqueous dispersion comprising an emulsifier and an emulsion stabilizer and preparing a feedstock comprising encapsulated particles by homogenizing the emulsion, and forming a plurality of coated particles by spray drying the feedstock, wherein resulting particles comprises a porous shell disposed on or over a core and the core comprises at least one hydrophobic seed particle.

Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients

The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.

Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules

Dry powder formulations for inhalation comprising spray-dried particles and their use in the treatment of an obstructive or inflammatory airways disease. Each particle has a core of a first active ingredient in substantially crystalline form that is coated with a layer of a second active ingredient in substantially amorphous form that is dispersed in a pharmaceutically acceptable hydrophobic excipient. A process for preparing such formulations is also described.

Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases

A method of preparing a pharmaceutical formulation comprises providing a solution comprising a first solvent, a second solvent, an active agent, and an excipient. The second solvent is less polar than the first solvent and the excipient is more soluble in water than the active agent. The first and second solvents are removed from the solution to produce particles comprising the active agent and the excipient. In one version, the excipient comprises an amino acid and/or a phospholipid. A pharmaceutical formulation made by a version of the invention comprises particles comprising an active agent and an excipient which at least partially encapsulates the active agent, wherein the excipient is more soluble in water than the active agent.

Pharmaceutical formulation comprising a water-insoluble active agent

The present invention comprises compositions and formulations comprising amphotericin B, compositions and formulations comprising amphotericin B with one or more excipients, methods of making amphotericin B compositions and formulations, as well as systems for using amphotericin B compositions and formulations. Also provided are pharmaceutical compositions comprising the formulation, methods of administering the pharmaceutical compositions and methods of treating patients with the pharmaceutical compositions.

Compositions comprising amphotericin B, mehods and systems

A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 &#x3bc;m to about 1.9 &#x3bc;m. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 &#x3bc;m to about 1.9 &#x3bc;m. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 &#x3bc;m, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.

Compositions comprising amphotericin B, methods, and systems

Growing community of inventors

San Carlos, CA, United States of America

Danforth Miller